Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. - Wikidata - awgldk - TriplyDB

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

http://www.wikidata.org/entity/Q37799850

about

Targeting heat shock proteins to modulate α-synuclein toxicity Protein degradation pathways in Parkinson's disease: curse or blessing Direct visualization of CHIP-mediated degradation of alpha-synuclein in vivo: implications for PD therapeutics Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90 Synthesis of macrolactam analogues of radicicol and their binding to heat shock protein Hsp90 Distinct roles of molecular chaperones HSP90α and HSP90β in the biogenesis of KCNQ4 channels Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss Heat shock protein responses to aging and proteotoxicity in the olfactory bulb.Heat shock proteins in neurodegenerative disorders and aging Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5).Gene therapy with mitochondrial heat shock protein 70 suppresses visual loss and optic atrophy in experimental autoimmune encephalomyelitis.Anti-inflammatory peptide regulates the supply of heat shock protein 70 monomers: implications for aging and age-related disease Heat shock protein defenses in the neocortex and allocortex of the telencephalon.Molecular chaperones in Parkinson's disease--present and future Involvement of Bcl-2-associated athanogene (BAG)-family proteins in the neuroprotection by rasagiline.A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo.α-Synuclein oligomers and clinical implications for Parkinson disease.Gene therapy for misfolding protein diseases of the central nervous system.Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.Super Spy variants implicate flexibility in chaperone action.Identification of chaperones in a MPP+-induced and ATRA/TPA-differentiated SH-SY5Y cell PD model.Proteomic profiling of mitochondria: what does it tell us about the ageing brain?Adaptation and sensitization to proteotoxic stress.BAG5 Interacts with DJ-1 and Inhibits the Neuroprotective Effects of DJ-1 to Combat Mitochondrial Oxidative Damage.Molecular chaperones as therapeutic targets to counteract proteostasis defects.Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond.Hsp70 protein complexes as drug targets.The role of amyloidogenic protein oligomerization in neurodegenerative disease.Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseases Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential anti-Parkinson agents.Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.BAG3 facilitates the clearance of endogenous tau in primary neurons.An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors--potential therapeutics in cancer and neurodegeneration.Silencing of Hsp90 chaperone expression protects against 6-hydroxydopamine toxicity in PC12 cells.Alpha-synuclein oligomers: a new hope.N-Acetyl-l-Cysteine Protects Astrocytes against Proteotoxicity without Recourse to Glutathione.Impact of aging on heat shock protein expression in the substantia nigra and striatum of the female rat.The contribution of mutant GBA to the development of Parkinson disease in Drosophila.

P2860

Q26827066-15B306B1-553F-4E6A-9615-150087CC827B Q27026029-9497CA61-46F5-4274-B69E-AD504B315729 Q27314815-44FD4149-6868-4391-9B94-7A7AA0769610 Q27676888-D9494F78-6FEC-4F3F-A248-1D8F1C894DFE Q27688922-9EC0D594-1819-4610-B91E-E5B2567D3B24 Q28115218-64BF20A1-2B4F-4871-8509-F9AE5998FBCA Q28538890-2BE14511-6E39-4DF5-BB23-5BBC988E89E5 Q30382422-F7ECE472-3E8E-42A9-AFF2-D8DA2DB1311B Q30414556-6B919C61-C76B-495B-91E3-A7EE7D0CDCDC Q33715640-4CD821F9-371F-44C5-AC85-5CF3E9FFF494 Q33831775-3F908865-3E7E-49BA-869B-4CE0746FA9D9 Q34069978-C73B96EF-E5FA-4A4A-A842-DA57C18E830B Q35485951-7C4DEABD-9502-4F44-9104-C04860493710 Q35561538-BB09B919-79BE-4A8C-820F-B326BA58F5DD Q35688796-5716258E-9587-4655-B589-F77A3D7B8829 Q36411750-B1B1A010-D463-4B40-A768-23559A8A7DC9 Q36475337-30CDE874-FF19-4F20-AE9D-2DBDACF40B84 Q36718306-ECFC6052-3F0A-4C03-BCF5-FDBA04F80BD6 Q36983203-974B1D14-50EF-4DDE-864C-7C73306B27AD Q37506492-D10EAF40-5C30-4F48-94F2-BD9A85E5AE38 Q37542104-0033EF81-4FA6-4A04-9272-B112A9D21B3F Q37553863-D43DB3D2-F017-4A62-95F4-7826E285D32F Q37610171-DBB50C4D-3522-468A-872B-AC02A6D00BCE Q37651678-DD1407CF-6065-4147-A4EE-730E948F73BE Q37703450-93CBB307-517E-40C0-9AE9-EFE16C5826B1 Q37880729-D36F69DE-C712-4664-A307-37B0CFE0B377 Q37880734-74FF67DB-BDE0-4379-A16F-003DC3C2B589 Q38037745-565AA960-F400-4951-AEFD-BD9A32BA2A08 Q38093118-F1C4BD79-7FAE-4E14-9A6A-89AE5B92037D Q38093796-3DCBBE98-F365-4068-9B24-788643A30761 Q38817063-E0F10FC2-FE43-4801-B07A-C84F0F1AF39C Q39048969-2F026635-0BD9-4FC0-93FF-C5D889CCCEC9 Q41623081-AE480DE0-8BDE-4C1F-9D08-EE7427501BBB Q41813298-0C096A23-9C26-4264-9725-870A91C2EB2B Q42875861-37E43B24-938A-4C7E-A85D-67355494494B Q45813546-D499C7C8-7546-4985-AE3C-0FA250197296 Q46321755-1F373F80-273B-45F7-848D-8A8DA7D1D6F7 Q47919698-36F765AF-88AB-450D-862D-69CD65866A6F Q51147143-88FA34C5-5107-4857-9792-519FFAFA96BD Q52848620-438E3B18-DD81-491F-957F-17018D69BE6B

P2860

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

http://www.wikidata.org/entity/Q37799850

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

@en

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

@nl

type

label

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

@en

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

@nl

prefLabel

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

@en

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

@nl

P1433

Q37799850-F1E7B0FF-C101-4A5C-843B-1995E5E6038E

P1476

Q37799850-CA535663-7344-46A6-9323-9364D3372360

P2093

Q37799850-64E5659A-C112-40E1-86BF-BB4533037C01

Q37799850-79086791-A05C-48E1-9C59-782AB983BD7F

Q37799850-C827FE87-2B57-42D3-B14F-1460DB2E1905

P2860

Q37799850-00800813-7843-4F14-BC07-781237439131

Q37799850-01BC6487-8326-4771-9C7C-E1548F9535ED

Q37799850-01D50834-AA98-4F49-97F8-D1CFD33F83D0

Q37799850-03B1FCD3-1FEA-4007-95C1-408A642734EF

Q37799850-049D26F6-58D2-4DB6-8687-84201FD4256C

Q37799850-06799A9F-BB97-4E4F-AEA5-85F93B39D897

Q37799850-0878276F-6A3C-4E61-83FE-931938B5EF4B

Q37799850-08B8C60A-8181-4A6A-ACDE-F0E41B3B4B47

Q37799850-0A357E1C-B954-4644-966D-3CCF36092475

Q37799850-0FD9F40D-A8C8-4D5B-8841-D6DE563D9647

P304

Q37799850-875ABF2A-158A-4E1E-A4D1-7145C9C13357

P31

Q37799850-A28D5B5B-B9CF-4E6E-8093-A0A020B6E4B0

P356

Q37799850-8BA6B006-0D4A-4E69-9A3E-89999ADE1747

P433

Q37799850-16414FDD-EBBF-4901-803C-7CF802395F7D

P478

Q37799850-68861373-ACB9-4E5A-86FE-0A15AC63DB65

P577

Q37799850-F1814F10-E878-44D3-87EF-790443B4A3A7

P5875

Q37799850-1BE5C7F6-83C8-41AB-A3CF-CE8262028006

P698

Q37799850-05A78BA4-E6A8-4933-99C9-C4DBD6CB379E

P921

Q37799850-4F15CCC8-D0D1-480F-B8F6-2E0E96534E47

Q37799850-6FE286B6-88FF-4619-B7F8-0117BEA2BE20

P932

Q37799850-10D1C208-23C4-4B5C-91C4-62FE72CF8485

P356

187152710793237386

P1433

CNS and Neurological Disorders

P1476

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

@en

P2093

L V Kalia

http://www.w3.org/2001/XMLSchema#string

P J McLean

http://www.w3.org/2001/XMLSchema#string

S K Kalia

http://www.w3.org/2001/XMLSchema#string

P2860

An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators

Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions

Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions.

RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination

The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins

Molecular markers of early Parkinson's disease based on gene expression in blood

Siah-1 facilitates ubiquitination and degradation of synphilin-1

CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity

Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip

Protein quality control during aging involves recruitment of the macroautophagy pathway by BAG3

P304

741-753

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/187152710793237386

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47413726

http://www.w3.org/2001/XMLSchema#string

P698

20942788

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

molecular chaperones

P932

3364514

http://www.w3.org/2001/XMLSchema#string